Retatrutide, a new dual stimulator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is exhibiting promising data in early patient studies. Ongoing research suggests https://single-bookmark.com/story21382618/retatrutide-emerging-investigations-and-potential-medical-uses